- Home
- OPK vs APLT Comparison
OPK vs APLT Comparison
Compare OPK & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- APLT
- Stock Information
- Founded
- OPK 2007
- APLT 2016
- Country
- OPK United States
- APLT United States
- Employees
- OPK N/A
- APLT N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- APLT Health Care
- Exchange
- OPK Nasdaq
- APLT Nasdaq
- Market Cap
- OPK 1.0B
- APLT 63.6M
- IPO Year
- OPK 1995
- APLT 2019
- Fundamental
- Price
- OPK $1.38
- APLT $0.42
- Analyst Decision
- OPK Buy
- APLT Buy
- Analyst Count
- OPK 4
- APLT 6
- Target Price
- OPK $2.75
- APLT $6.10
- AVG Volume (30 Days)
- OPK 1.9M
- APLT 876.2K
- Earning Date
- OPK 11-06-2025
- APLT 11-06-2025
- Dividend Yield
- OPK N/A
- APLT N/A
- EPS Growth
- OPK N/A
- APLT N/A
- EPS
- OPK N/A
- APLT N/A
- Revenue
- OPK $664,029,000.00
- APLT $121,000.00
- Revenue This Year
- OPK N/A
- APLT N/A
- Revenue Next Year
- OPK $0.84
- APLT $5,931.24
- P/E Ratio
- OPK N/A
- APLT N/A
- Revenue Growth
- OPK N/A
- APLT N/A
- 52 Week Low
- OPK $1.11
- APLT $0.30
- 52 Week High
- OPK $2.04
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- OPK 50.29
- APLT 38.07
- Support Level
- OPK $1.34
- APLT $0.43
- Resistance Level
- OPK $1.44
- APLT $0.46
- Average True Range (ATR)
- OPK 0.04
- APLT 0.03
- MACD
- OPK -0.00
- APLT -0.01
- Stochastic Oscillator
- OPK 40.00
- APLT 11.08
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.